Serum Adiponectin as an Early Marker for Renal Impairment in Patients With Non-alcoholic Fatty Liver Disease.

• Conditions: Non-Alcoholic Fatty Liver Disease
• Interventions: Diagnostic Test: serum Adiponectin

• Registration Number: NCT05106049
• Lead Sponsor: Assiut University

Brief Summary

Early detection of renal impairment in patients with non-alcoholic fatty liver disease and its correlation with serum Adiponectin level.

Detailed Description

Detection of serum Adiponectin by ELISA technique using (EIA-3418) KIT, DRG international inc., USA

Study Timeline

• Status Verified: 2021-10
• Study First Submitted: 2021-10-23
• Study First Submitted QC: 2021-10-23
• Last Update Submitted: 2021-10-23
• Study First Posted: 2021-11-03
• Last Update Posted: 2021-11-03
• Study Start: 2021-12
• Primary Completion: 2022-12
• Study Completion: 2023-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• Patients with fatty liver aged from 18 to 60 yrs either diabetic or not .
• Patient with normal echogenic kidney in ultrasound and eGFR more than 60 mL/min/1.73m2.
• The Control group are completely healthy subjects without any systemic or liver and kidney affection

Exclusion Criteria

• Patients less than 18 yrs & more than 60 yrs .
• All patients having any other causes of renal and hepatic disease rather than Diabetes and having any other systemic problem.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
cases	serum Adiponectin	non-alcoholic fatty liver patients
control	serum Adiponectin	healthy persons

Primary Outcome Measures

Name	Time	Method
Correlate serum Adiponectin level with renal impairment in non-alcoholic fatty liver disease.	baseline	measure level of serum Adiponectin in non-alcoholic fatty liver patients to detect early renal impairment.